Sanderling Venture Partners Vi Buys 86,867 Shares of CalciMedica, Inc. (NASDAQ:CALC) Stock

CalciMedica, Inc. (NASDAQ:CALC) major shareholder Sanderling Venture Partners Vi bought 86,867 shares of the stock in a transaction dated Friday, November 1st. The stock was purchased at an average price of $3.75 per share, with a total value of $325,751.25. Following the acquisition, the insider now directly owns 814,300 shares in the company, valued at approximately $3,053,625. The trade was a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

CalciMedica Price Performance

Shares of CALC stock opened at $3.50 on Thursday. CalciMedica, Inc. has a fifty-two week low of $2.68 and a fifty-two week high of $8.38. The stock’s 50-day simple moving average is $4.23 and its 200-day simple moving average is $4.63.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.03. As a group, equities analysts predict that CalciMedica, Inc. will post -2.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CALC has been the subject of a number of recent analyst reports. HC Wainwright lowered their target price on shares of CalciMedica from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Monday. Oppenheimer increased their target price on CalciMedica from $14.00 to $20.00 and gave the company an “outperform” rating in a research report on Wednesday, July 10th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in CalciMedica stock. Atria Investments Inc lifted its position in shares of CalciMedica, Inc. (NASDAQ:CALC) by 136.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,503 shares of the company’s stock after purchasing an additional 15,296 shares during the quarter. Atria Investments Inc owned 0.25% of CalciMedica worth $117,000 as of its most recent SEC filing.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.